TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

J&J wins U.S. approval for TB tablet

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

JNJ $70.10 +$0.62

at close on MONDAY

By Anna Edney C.2012 Bloomberg News
Monday, Dec. 31, 2012, 10:30 p.m.
 

Johnson & Johnson won regulatory approval for its tuberculosis tablet Sirturo, the first drug in 40 years that provides a new way to treat the contagious lung infection.

The Food and Drug Administration cleared Sirturo to be added to therapies for use by adults whose illness is resistant to multiple medicines, the New Brunswick, N.J.- based company said Monday.

While tuberculosis was once the leading cause of death in the nation, the drug-resistant version of the illness affected about 98 people last year, according to the Centers for Disease Control and Prevention.

Subscribe today! Click here for our subscription offers.

 

 


Show commenting policy

Most-Read Business Headlines

  1. GNC to expand testing of supplements in settlement with NY
  2. Stafford: Hirers bemoan wasted time with some applicants
  3. If you get this letter from the IRS, it’s legitimate
  4. Tourists rush to visit Cuba before American influence felt
  5. Federal Trade Commission cracks down on crooked vehicle sales
  6. Increased credit card use reflects confidence, flat wages
  7. Loss of Costco staggers credit card giant
  8. Venting online about job protected
  9. Home appraisal is below sales price — now what?
  10. Farmers fund research on gluten-free wheat
  11. American Eagle Outfitters to add stores in Chile, Peru